Literature DB >> 11052272

Plasma levels of endothelin-1 in patients with the hepatorenal syndrome after successful liver transplantation.

S Bachmann-Brandt1, I Bittner, P Neuhaus, U Frei, R Schindler.   

Abstract

The hepatorenal syndrome (HRS) is characterized by renal vasoconstriction leading to deterioration of renal function in patients with liver disease. A possible role of endothelin-1 (ET-1) in the pathogenesis of HRS has been suggested, but a correlation between ET-1 plasma levels and the development of HRS as well as the recovery from HRS following OLT has not been shown yet. We performed longitudinal measurements of ET-1 plasma levels in four groups of patients, 5 patients with HRS before and after orthotopic liver transplantation (OLT), 10 patients without HRS undergoing OLT, 20 patients with chronic renal failure but without liver disease, and 12 healthy controls. Before OLT, plasma levels of ET-1 were higher in patients with HRS (19.5 +/- 8.6 ng/l, P < 0.001; n = 5) compared to patients without HRS (4.9 +/- 1.1 ng/l; n = 10), normals (1.2 +/- 0.18 ng/l; n = 12), and patients with chronic renal failure (2.4 +/- 0.4 ng/l; n = 20). Patients with HRS compared to patients without HRS had higher levels for creatinine (2.42 +/- 0.6 vs. 0.89 +/- 0.05 mg/dl, P < 0.05), creatinine clearance (107 +/- 9 ml/min vs. 44.6 +/- 5.5 ml/ min, P < 0.001), and bilirubin (11.4 +/- 3.8 vs. 3.7 +/- 1 mg/dl, P < 0.05) before OLT. Within one week after OLT, there was a rapid decrease in ET-1 levels in patients with HRS while creatinine and bilirubin levels decreased slower. Regression analysis revealed a weak correlation between serum creatinine and ET-1 (r = 0.192, P = 0.04) and a significant correlation between serum bilirubin and ET-1 (r = 0.395, P < 0.001). The means of the ET-1 levels decreases rapidly with improvement of liver function after OLT. Levels of ET-1 correlate with excretory liver function assessed by bilirubin. The fall in ET-1 levels preceding improvement of renal function further strengthens the concept of ET-1 being a causative factor in HRS.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11052272     DOI: 10.1007/s001470050714

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  6 in total

1.  Effects of orthotopic liver transplantation on vasoactive systems and renal function in patients with advanced liver cirrhosis.

Authors:  Concepcíon Cassinello; Enrique Moreno; Adolfo Gozalo; Blanca Ortuño; Beatriz Cuenca; José Antonio Solís-Herruzo
Journal:  Dig Dis Sci       Date:  2003-01       Impact factor: 3.199

Review 2.  Renal dysfunction in cirrhosis: diagnosis, treatment and prevention.

Authors:  Elaine Yeung; Elaine Yong; Florence Wong
Journal:  MedGenMed       Date:  2004-12-02

Review 3.  Endothelin B receptor, a new target in cancer immune therapy.

Authors:  Lana E Kandalaft; Andrea Facciabene; Ron J Buckanovich; George Coukos
Journal:  Clin Cancer Res       Date:  2009-06-30       Impact factor: 12.531

4.  Endothelin-1/Nitric Oxide Ratio as a Predictive Factor of Response to Therapy With Terlipressin and Albumin in Patients With Type-1 Hepatorenal Syndrome.

Authors:  Ahmed Abdel-Razik; Nasser Mousa; Mostafa Abdelsalam; Ahmed Abdelwahab; Mona Tawfik; Ahmed M Tawfik; Ahmad S Hasan; Rania Elhelaly; Niveen El-Wakeel; Waleed Eldars
Journal:  Front Pharmacol       Date:  2020-01-31       Impact factor: 5.810

5.  Endothelin and vascular function in liver disease.

Authors:  K Moore
Journal:  Gut       Date:  2004-02       Impact factor: 23.059

Review 6.  Hepatorenal syndrome in children: a review.

Authors:  Sarah Tayná de Carvalho; Pollyanna Faria Fradico; Maria Luiza Barreto Cazumbá; Ramon Gustavo Bernardino Campos; Priscila Menezes Ferri Liu; Ana Cristina Simões E Silva
Journal:  Pediatr Nephrol       Date:  2020-10-01       Impact factor: 3.714

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.